KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Finished Goods: 2018-2025

Historic Finished Goods for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Sep 2025 value amounting to $1.8 million.

  • Rigel Pharmaceuticals' Finished Goods fell 69.37% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 69.37%. This contributed to the annual value of $5.0 million for FY2024, which is 232.49% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Finished Goods stood at $1.8 million, which was down 33.97% from $2.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Finished Goods high stood at $5.8 million for Q3 2024, and its period low was $962,000 during Q1 2021.
  • In the last 3 years, Rigel Pharmaceuticals' Finished Goods had a median value of $2.4 million in 2023 and averaged $3.0 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Finished Goods surged by 232.49% in 2024, and later slumped by 69.37% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Finished Goods (Quarterly) stood at $1.3 million in 2021, then soared by 45.12% to $1.9 million in 2022, then dropped by 20.80% to $1.5 million in 2023, then surged by 232.49% to $5.0 million in 2024, then plummeted by 69.37% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.7 million for Q2 2025, and $3.8 million during Q1 2025.